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Abstract
Oxidative stress is a determining factor in the pathophysiology of heart disease. This study aimed at evaluating the protec-
tive activity of Abengourou Forastero cocoa in doxorubicin-induced cardiotoxicity in rats. Thirty (30) wistar rats divided into 5
groups were orally pretreated with distilled water, resveratrol (25 mg/kg/day) or defatted Abengourou Forastero cocoa powder
(1000 and 1500 mg/kg/day) for sixty (60) consecutive days. A single dose of doxorubicin (15 mg/kg/day) was administered on
day 59 by intraperitoneal route. The biochemical parameters were assessed and a histological examination of the heart was
performed. This study showed that doxorubicin treated animals exhibited a significant increase of alanine aminotransferase, as-
partate aminotransferase, lactate dehydrogenase, phosphocreatine kinases, creatine kinases, total cholesterol, triglycerides, and
LDL-cholesterol levels in serum. However, a decrease of HDL-cholesterol and an alteration of cardiac tissue were noticed. Pre-
ventive treatment with Abengourou Forastero cocoa at doses of 1000 and 1500 mg/kg significantly reduced the biochemical and
histological alterations induced by doxorubicin. Results showed that Abengourou Forastero cocoa protects and prevents against
doxorubicin-induced cardiac damage.
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Introduction
The heart is a vital organ of the human body, and despite all nat-
ural protective systems, is particularly vulnerable to toxic sub-
stances that can damage and disrupt its functions [1, 2]. The
prevalence of heart disease remains very high in Africa, due
to some risk factors such as smoking, alcoholism, physical in-
activity, malnutrition, self-medication and environmental condi-
tions [3, 4].
Therefore, toxins, drugs and hyperlipidemic diets play a key
role by increasing oxidative stress [5, 6]. Cells or tissues some-
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times suffer aggressions when they are subjected to endogenous
or exogenous production of oxygen free radicals that go beyond
their antioxidant capacities [7]. Our body has developed mecha-
nisms to eliminate these free radicals. Thus, superoxide dismu-
tases (SOD) are able to remove the superoxide anion by the dis-
mutation reaction, forming, with two peroxides, an oxygen and a
hydrogen peroxide molecule. As for reduced glutathione, it pro-
tects against oxygen radicals and peroxides or nitrogen monox-
ide (NO-). However, regarding the excessive release of free rad-
icals that disrupt our antioxidant defense system, dietary sup-
plementation with antioxidants such as polyphenols is strongly
recommended [8].
In recent years, there has been a growing interest in plants
with high polyphenol contents. This study highlighted the use of
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several natural or synthetic compounds with antioxidant proper-
ties to prevent and treat oxidative stress induced diseases [9, 10].
Among them, cocoa ranks high [11, 12].
Indeed, cocoa is an important source of polyphenols and ac-
count for 12 to 18% of its total dry weight, these are mainly
flavonoids and phenolic acids. Its flavonoid content is much
higher than that of green tea and red wine leaves [13]. The
studies of [14] showed that Abengourou Forastero cocoa, a city
in eastern Côte d’Ivoire, has a high polyphenol content with
high antioxidant activity. According to these outstanding char-
acteristics, the aim of this study is to investigate the effects
of Abengourou Forastero cocoa intake against doxorubicin-
induced damage in the heart of experimental rats. Thus, the bio-
chemical parameters were assessed and a histological examina-
tion of the heart was performed.
Material and methods
Preparation of cocoa powder samples
Selected cocoa pods were harvested using a large knife and then
split open with a club. Collected Cocoa beans were collected and
then fermented at the edge of plantation for five days on a black
tarpaulin and covered with banana leaves. After fermentation,
cocoa beans were spread in the sun on a black tarpaulin for dry-
ing from 7 am to 4 pm for ten days. Beans were then peeled,
crushed and manually degerminated using a knife. Cotyledons
were ground with an electric mill (VIKING GE 150, Japan) to
obtain cocoa mass which was pressed in a white cloth using a tra-
ditional press machine to extract cocoa butter. Finally, the press
cake was ground in a mortar to give a fine cocoa powder used
for pharmacological studies.
Experimental animals
Albino rats of Wistar strain (Rattus norvegicus) were used as ex-
perimental animals. Rats were raised at the animal house of the
teacher training school in Abidjan (Côte d’Ivoire). They were
between 2 and 3 months of age and weighing 150 -180 g. Animal
were group-housed with 3 rats per plastic cage and kept at room
temperature (29 ± 1◦C) on a 12 h light/dark cycle. Rats had
free access to water and food (food pellets and dry corn). The
experiments were approved by the Ethical Committee of Health
Sciences of University Félix Houphouët-Boigny (Côte d’Ivoire).
These guidelines were in accordance with the European Council
Legislation 86/609/EEC for the protection of experimental ani-
mals [15].
Study design
Animals were randomly divided into five (5) groups of six (6)
rats:
• NORM Group (Normal control): received distilled water
(1 mL/100 g body weight) by oral route for 60 consecutive
days. On day 59, a solution of NaCl 0.9 % (0.5 mL/100g
body weight) was intraperitoneally injected to rats.
• DOXO Group (intoxicated control): received distilled wa-
ter (1 mL/100 g body weight) by oral route for 60 con-
secutive days. On day 59, doxorubicin (0.5 mL/100g body
weight) was intraperitoneally injected to rats.
• REF Group (resveratrol, 25 mg/kg body weight). Received
by oral route 1 mL / 100 g body weight of resveratrol
(2.5 mg/ mL) for 60 consecutive days. On day 59, dox-
orubicin (0.5 mL/100g body weight) was injected to rats
by intraperitoneal route.
• Group C1 (1000 mg/kg body weight of cocoa). Received
by oral route 1 mL / 100 g body weight of cocoa (0.1 g/
mL) for 60 consecutive days. On day 59, doxorubicin (0.5
mL/100g body weight) was injected to rats by intraperi-
toneal route.
• Group C1.5 (1500 mg/kg body weight of cacao). Received
by oral route 1 mL / 100 g body weight of cocoa (0.15 g/
mL) for 60 consecutive days. On day 59, doxorubicin (0.5
mL/100g body weight) was injected to rats by intraperi-
toneal route.
On completion of the experiment, the animals were anesthetized
24h later using diethyl ether and blood sample was collected
from the carotid artery. Two (2) ml of blood was collected in
a dry tube and centrifuged at 3000 rpm for 10 min and serum
was collected to assess biochemical parameters. Then, each ani-
mal heart was collected, weighed, rinsed with distilled water and
preserved in 10% formalin for histopathological studies.
The relative heart weight of each animal was evaluated as
followed:
RHW = HW/BWD61
• RHW : Relative Heart Weight
• HW : Heart Weight
• BWD61: Body weight of rat on day 61.
Biochemical analyses
Biochemical parameters such as Alanine aminotransferase
(ALAT), Aspartate aminotransferase (ASAT), lactate dehydro-
genase (LDH), phosphocreatine kinases (CPK), creatine kinases,
total cholesterol, triglycerides (TG), LDL cholesterol (LDL-C)
and HDL cholesterol (HDL-C) were investigated by an auto-
mated analyzer (Cobas C311 HITACHI ROCHE, France) using
a commercial kits according to the manufacturer’s instructions.
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Histopathological assay
Techniques used by Coujard et al [16] were adopted for this
study. Samples preserved in aqueous formalin were successively
dehydrated in five successive ethanol baths for 15 minutes each.
The first two baths had respective concentrations of 70% and
90%. The other three contained absolute ethanol 96% pure. Tis-
sues were embedded in toluene. The impregnation was carried
out in an oven at 60◦C in two successive paraffin wax for one
hour each. The inclusion was performed in paraffin after solid-
ification. Sections of tissues were cut at 5µm thickness using a
microtome (Microm) and were stained with hematoxylin-eosin
(H&E) solution. Finally, stained sections were examined under
a light microscope Zeiss with an incorporated camera (Sony).
Data analysis
Data were analyzed using the software Graph Pad Prism 5.0 (Mi-
crosoft, USA). Comparison of means were performed with one-
way analysis of variance (ANOVA) followed by Tukey’s post-
hoc test. Statistical significance was considered at p < 0.05.
Results
Effect of treatments on cardiac enzyme parameters
As shown in table 1 serum enzyme activities of ALAT, ASAT,
LDH, CPK and CK-MB of DOXO-group (intoxicated control
group) were significantly higher (p <0.001) compared to NORM
group (normal control group). However, administration of cocoa
powder or resveratrol to groups of intoxicated and treated an-
imals (C1, C1.5 or REF) resulted in significantly lower level
(p < 0.001) of ALAT, ASAT, LDH, CPK and CK-MB activ-
ity in serum compared with DOXO group (intoxicated control
group). Thus, these activities did not reach those of normal con-
trol group.
Effect of treatments on serum lipid profile
Results tabulated in Table 2 indicated a significant increase
(p < 0.001) level in total cholesterol, triglycerides and LDL-
cholesterol and however an obvious significant decrease (p <
0.001) in HDL-cholesterol level in DOXO group compared with
normal control group was observed.
These results also showed that treatment with cocoa powder
at doses of 1 g/kg Pc (C1) or 1.5 g/kg Pc (C1.5) or resveratrol
at a dose of 25 mg/kg Pc (REF group) promoted a significant
decrease (p < 0.001) in total cholesterol, triglycerides and LDL-
cholesterol level and an increase in HDL- cholesterol level com-
pared with the DOXO group.
Effects of different treatments on the relative heart weight
of rats
Results in Figure 1 indicated that the relative heart weight of
normal control group (0.31 ± 0.02%) was significantly lower (p
< 0.001) compared with DOXO group (0.45 ± 0.03%). Treat-
ments with cocoa powder at doses of 1 g / kg body weight(C1)
or 1.5 g / kg body weight (C1.5) or resveratrol at a dose of 25
mg / kg of body weight (REF group) caused a significant (p <
0.001) decrease in relative heart weight compared with DOXO
group.
Effects of different treatments on rats heart structure
The histology of rats’ heart tissues in the normal control group
(NORM group) showed normal morphological aspects while the
Doxorubicin treated group (DOXO group) exhibited morpholog-
ical abnormalities such as severe myocardial necrosis with loss
of myofibrils. Histology of heart tissues in resveratrol treated
group (REF group) or cocoa powder treated groups at doses of 1
g / kg body weight (group C1) or 1.5 g / kg body weight (group
C1.5) showed a decrease in Doxorubicin effects.
Discussion
Doxorubicin is an efficient and widely used chemotherapeutic
agent. However, its clinical use is limited on account of its dose-
dependent cardiotoxicity [17]. Experimental studies have proved
that doxorubicin induces oxidative stress by releasing free rad-
icals in myocardial cell [18]. Reactive oxygen species such as
superoxide and hydroxyl radicals are likely to cause damage to
various intracellular components. The myocardial tissue is par-
ticularly sensitive to free radical damage because it contains low
levels of radical detoxifying enzymes such as superoxide dismu-
tase (SOD), glutathione peroxidase (GSH) and catalase (CAT).
Moreover, doxorubicin has high affinity for mitochondrial
membrane phospholipids in cardiac myocytes, leading to dox-
orubicin accumulation in myocardial cell [19]. Doxorubicin ac-
cumulation in mitochondrial is hazardous for the heart since it
could provoke extreme adverse effects on cardiac myocytes con-
tractile function by altering energy metabolism [20].
Thus, doxorubicin-induced myocardial cell injury in rats is
indicated by a high level of serum enzyme markers such as lac-
tase dehydrogenase (LDH), phosphocreatine kinase (CPK) and
transaminases ( [21]. Increasing LDH levels in serum and extra-
cellular fluid suggest a leakage of this enzyme from mitochon-
dria as a result of doxorubicin-induced toxicity in animals. The
above mentioned biochemical parameters were used as markers
in other studies to assess cardiotoxicity [22].
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NORM DOXO REF C1 C1.5
ALAT (UI/L) 82.2±3.3 169.8±7.3∗∗∗ 103.2±5.3∗∗∗+++ 119.5±2.4∗∗+++ 113.7±5.2∗∗∗+++
ASAT (UI/L) 114.2±4.7 190.3±5.1∗∗∗ 133.0±3.3∗∗∗+++ 144.5±3.0∗∗∗+++ 139.2±3.2∗∗∗+++
LDH (UI/L) 2187±38 3118±52∗∗∗ 2301±23∗∗∗+++ 2525±30∗∗∗+++ 2495±17∗∗∗+++
CPK (UI/L) 2016±26 3107±27∗∗∗ 2105±14∗∗∗+++ 2300±16∗∗∗+++ 2228±21∗∗∗+++
CK-MB (UI/L) 932±18 1378±24∗∗∗ 1005±17∗∗∗+++ 1098±26∗∗∗+++ 1056±13∗∗∗+++
Data are presented as the mean ± SD (standard error) n= 6.* P < 0.05; ** P < 0.01; *** P < 0.001: significant difference
compared with NORM group. + P < 0.05; ++ P < 0.01; +++ P < 0.001: significant difference compared with DOXO
group.




NORM DOXO REF C1 C1.5
C-T (UI/L) 0.62±0.02 1.04±0.02∗∗∗ 0.79±0.03∗∗∗+++ 0.80±0.02∗∗∗+++ 0.78±0.02∗∗∗+++
TG (UI/L) 05.3±00.1 0.69±0.02∗∗∗ 06.0±0.01∗∗∗+++ 0.60±0.02∗∗∗+++ 05.9±0.02∗∗∗+++
HDL-C (UI/L) 02.5±0.02 0.13±00.1∗∗∗ 0.23±0.02+++ 0.23±0.01+++ 0.22±0.02∗+++
LDL-C (UI/L) 0.23±0.02 0.69±0.02∗∗∗ 0.40±0.02∗∗∗+++ 0.42±0.01∗∗∗+++ 0.41±0.02∗∗∗+++
Data are presented as the mean ± SD (standard error) n= 6. * P < 0.05; ** P < 0.01; *** P < 0.001: significant
difference compared with NORM group. + P < 0.05; ++ P < 0.01; +++ P < 0.001: significant difference compared
with DOXO group.
Figure 1 Effects of cocoa powder and resveratrol on relative heart weight. Data are presented as the mean ±SD (standard error) n= 6. * P < 0.05;
** P < 0.01; *** P < 0,001:significant difference compared with NORM group. + P < 0.05; ++P < 0.01; +++ P < 0.001: significant difference
comparedwith DOXO group.
NORM group: distilled water +NaCl, DOXO group: distilled water +doxorubicin (15 mg/ Kg), REF group:resveratrol (25 mg / Kg) + doxorubicin (15
mg / Kg), group C1: cocoapowder (1 g / Kg) + doxorubicin (15 mg/ Kg), group C1.5: cocoa powder (1.5g / Kg) + doxorubicin (15 mg/ Kg).
Abengourou Forastero cocoa powder or resveratrol inhibits
the release of CPK, LDH and transaminases induced by dox-
orubicin in rats’ serum. It is widely reported that the produc-
tion of free radicals induced by doxorubicin triggers off mem-
brane peroxidation and disruption of cardiac myocytes, promot-
ing a large release of CPK level in serum. However, Abengourou
Forastero cocoa powder administered to animals inhibit the re-
lease of CPK, LDH and transaminases resulting in an outstand-
ing restoration of serum enzyme activities. These results are in
agreement with those of Murat et al. [23].
In addition, increase levels of plasma triglycerides, total
cholesterol, and low density lipoprotein (LDL) in doxorubicin
treated rat show that this antibiotic may interfere with lipid
metabolism or biosynthesis. Pretreatment with cocoa powder
or resveratrol decreased blood lipid level with an increase in
high density lipoprotein (HDL) level. Indeed, the decrease
in blood lipids and the increase in HDL-cholesterol in cocoa
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treated groups of animals may be due to polyphenols. The
lipid-lowering effect of cocoa is due to the inhibition of hepatic
cholesterol biosynthesis, to an increase secretion of fecal bile
acids and stimulation of LDL-cholesterol catabolism receptors
and to an increase uptake of LDL-cholesterol in blood by the
liver [24]. This lipid profile improvement could better heart
activity.
Improvement of lipid parameters could be due to cocoa but-
ter, composed of stearic acid (35%), palmitic acid (25%), oleic
acid (35%) and linoleic acid (2%). Cocoa butter therefore, con-
tains 60% of saturated fatty acid [11]. Several studies showed
a correlation between diets rich in saturated fatty acid and an
increase in total cholesterol. The current nutrition trend is to
minimize the intake of saturated fatty acids that increase blood
LDL-cholesterol, a risk factor for cardiovascular disease. How-
ever, the "atherogenic power" of saturated fatty acids depends on
chain length and the body’s ability to metabolize them [25].
While palmitic acid enhances production of LDL-cholesterol,
stearic acid, which is predominant in cocoa, is considered non-
atherogenic. Indeed, according to Chaveron [26] and Keen et
al. [11], once in the intestine, it is metabolized to oleic acid.
Thus, oleic acid, its precursor and linoleic acid (polyunsaturated
acid) in cocoa butter could promote an uptake of cholesterol to
the liver for its elimination. This elimination could help reduc-
ing total cholesterol level in the body for a better cardiac activ-
ity [27].
What is more, the histopathological assay revealed that Aben-
gourou Forastero cocoa powder alleviate alteration of heart tis-
sue in cocoa powder treated groups of rats (Group C1 and Group
C1.5) compared with DOXO group. These results confirm the
ability of Abengourou Forastero cocoa to reduce toxic effects of
doxorubicin by restoring normal cardiac physiology disrupted
by this cardiotoxic substance (doxorubicin).
Conclusion
The results of this study revealed that Abengourou Forastero co-
coa powder alleviate doxorubicin-induced cardiac cell damage.
Therefore the use of this cocoa is strongly recommended to pro-
tect and prevent against heart damage. This protective activity
was exhibited by an improvement in heart biochemical parame-
ters and by a significant decrease in relative heart weight. This
protective activity was significant at a dose of 1 g / kg body
weight and its mechanism could be based on their antioxidant
and antiradical activities due to phenolic compounds.
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